Approval · Notice of Compliance 30911 · 2023
CLONIDINE: Notice of Compliance 30911
Issued June 1, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30911
- Date
- June 1, 2023
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Manufacturers
- Canadian reference product
- TEVA-CLONDINE (Teva Canada Limited)
Products in this notice
Medicinal ingredients
- CLONIDINE HYDROCHLORIDE 0.1 MG per TAB
- CLONIDINE HYDROCHLORIDE 0.2 MG per TAB